Summit Therapeutics Inc.

1. 01

   Below its 50-day average, above its 200-day

   The 4 Nov 2026 close of $16.17 was 0.2% below its 50-day average ($16.21) and 0.1% above its 200-day average ($16.16). It has closed above the 200-day for 1 session, since 4 Nov 2026. The 50-day average crossed above the 200-day on 4 Nov 2026, in the latest session.

   Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026

2. 02

   Behind SPY and its sector fund XLV over 1 year

   1 month: −6.6% (SPY −1.6%, XLV +13.5%). 3 months: +19.5% (SPY −0.4%, XLV +15.5%). 1 year: −7.5% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.

   Daily closes, split-adjusted: SMMT, SPY and XLV · as of 4 Nov 2026

3. 03

   7.0 days to cover short interest

   40.9M shares were sold short at the 15 Oct 2026 settlement, 5.1% of the 799.7M shares outstanding; covering them would take 7.0 days of average volume. Short interest is reported twice a month, on a lag.

   Exchange short-interest filing · as of 15 Oct 2026

4. 04

   24% of the way up its 52-week range

   Closed at $16.17 on 4 Nov 2026: 44.7% below the 52-week high of $29.23 (21 Apr 2026) and 34.0% above the low of $12.07 (17 Aug 2026).

   Daily price bars, split-adjusted · as of 4 Nov 2026

At the 4 Nov 2026 close